{
    "abstractText": "In the Original Investigation titled \u201cAssociation of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis,\u201d1 published August 16, 2022, author Fabio Conforti\u2019s affiliations incorrectly included the Oncology Unit, Humanitas, Gavalleni, Bergamo, Italy. Dr Conforti\u2019s correct affiliation is the Division of Melanoma, Sarcomas, and Rare Tumors, European Institute of Oncology, Milan, Italy. This article has been corrected.1",
    "authors": [],
    "id": "SP:8322517e0ebf8e5ba8dee263313a1f89f602285d",
    "references": [
        {
            "authors": [
                "L Pala",
                "I Sala",
                "C Oriecuia"
            ],
            "title": "Association of anticancer immune checkpoint inhibitors with patient-reported outcomes assessed in randomized clinical trials: a systematic review and meta-analysis",
            "venue": "JAMA Netw Open",
            "year": 2022
        }
    ],
    "sections": [
        {
            "text": "In the Original Investigation titled \u201cAssociation of Anticancer Immune Checkpoint Inhibitors With Patient-Reported Outcomes Assessed in Randomized Clinical Trials: A Systematic Review and Meta-analysis,\u201d1 published August 16, 2022, author Fabio Conforti\u2019s affiliations incorrectly included the Oncology Unit, Humanitas, Gavalleni, Bergamo, Italy. Dr Conforti\u2019s correct affiliation is the Division of Melanoma, Sarcomas, and Rare Tumors, European Institute of Oncology, Milan, Italy. This article has been corrected.1"
        }
    ],
    "year": 2022
}